Managed

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on horizon

By

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Senators press Gilead over Sovaldi price

Senators press Gilead over Sovaldi price

By

In the latest chapter in the Sovaldi pricing saga, Senators Ron Wyden and Charles Grassley urge Gilead to clarify Sovaldi sticker shock.

Experiment cuts cancer costs, ups drug spend

UnitedHealthcare finds drug costs more than doubled.

France ponders off-label Avastin

French lawmakers have the chance to vote for off-label use of Avastin, potentially eating into the turf of higher-priced Lucentis.

Insurers put in bid for biosimilar naming

Health insurers and pharmacies signed a letter asking the FDA to require biosimilars and branded biologics to share the same name.

Omega-3 drugs angle for trig-lowering awareness

Omega-3 drugs angle for trig-lowering awareness

By

Celebrity endorsement, co-pay cards and online edutainment are some of the ways marketers are dueling for attention in the prescription omega-3 space.

CMS site guides patients through insurance coverage

The Centers for Medicare and Medicaid Services launched a new site Monday to help patients understand how to use their health coverage.

Italy: Use Avastin off-label

The Italian Medicines Agency is guiding patients away from Roche's costlier AMD-indicated Lucentis.

Oregon seeks HCV Rx waiver

The Oregon Health Plan wants to keep hep. C medications Sovaldi and Olysio off its list of covered treatments.

CVS specialty goes retail

CVS specialty goes retail

By

Patients will now be able to submit specialty prescriptions at the national chain's retail stores.

Insurers pay docs to stick to regimens

Companies including WellPoint and Highmark are deploying financial incentives for doctors to stick with recommended cancer treatments.

Teachable moment for new allergy tabs

Teachable moment for new allergy tabs

By

With pollen season approaching its peak, drugmakers are educating doctors on a new class of allergy tablets. It could be a while before they're made available for patients.

Ad chides Gilead "greed" over Sovaldi pricing

The AIDS Healthcare Foundation took out an ad in some WSJ editions saying the drug threatens to "break the bank."

Janssen submits HCV combo to FDA

The drugmaker sent Olysio + Sovaldi to regulators for an additional indication in HCV patients with liver scarring.

Survey finds pharma and payers not aligned

Survey finds pharma and payers not aligned

By

An EY report finds that pharma is not only failing to give payers the right type of drug data, but that industry has a lot of trust-building to do before they will accept it.

Bloomberg scrutinizes drug pricing

An analysis by Bloomberg today shows why drug pricing "keeps defying the law of gravity."

Diabetes costliest among non-specialty Rx

Diabetes costliest among non-specialty Rx

By

Express Scripts said treatments for diabetes are the most expensive of the traditional medications, while specialty drugs are eating up a significant portion of total drug spend.

Merck diversifies its Big Data agenda

Merck diversifies its Big Data agenda

By

Merck has broadened its analytics approach to include team-ups with a slate of organizations at the intersection of Big Data and health IT.

Young adult ACA enrollment holds steady

Around 25% of 18-34 year-olds have signed up for coverage. Obama's FunnyorDie appearance drives HHS traffic.

Managed Markets: Operation Patient-Centricity

Managed Markets: Operation Patient-Centricity

As the Affordable Care Act rolls out, the behaviorists at MicroMass surveyed stakeholders about the impact on industry. Jessica Brueggeman sorts out the diverse views and asks: Can healthcare reform lead pharma to operationalize its patient focus?

Retail pharmacies up consumer satisfaction

Retail pharmacies up consumer satisfaction

By

A study shows consumers are increasingly pleased with retail pharmacies, compared to mail order pharmacies, which are often considered a key means of driving adherence and lowering healthcare coverage costs.

CMS projects healthcare spending to rise

CMS projects healthcare spending to rise

By

Researchers says growth will average 5.8% a year between 2012 and 2022. They also anticipate generics will hit a leveling-off point that will drive average Rx prices upwards

Researchers propose new Rx adherence model

Researchers propose new Rx adherence model

By

Researchers say using additional data points offers greater insight into patient-adherence patterns.

Employer, employee healthcare costs to rise in 2014

By

Benefits research studies show employers expect to lay out 7% more in healthcare costs in 2014, a move that has not been accompanied by lower employee costs.

CVS joins prescription crackdown

By

The drugstore chain says it has cut off over-prescribers of tightly controlled medications.

Eylea outduels Lucentis for physician mindshare, survey shows

Eylea outduels Lucentis for physician mindshare, survey shows

By

Data show doctors are increasingly leaning on Regeneron's Eylea over Roche's Lucentis, as the two battle for share of the wet-AMD market.

Managed Markets: Pursuing the Payer

Managed Markets: Pursuing the Payer

While payers' proclivity for print is well-known, many prefer to receive pharma resources digitally, research shows. Joe Dysart on tools that work for this segment.

Email Newsletters